| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITGB7 |
| Uniprot No | P26010 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-140aa |
| 氨基酸序列 | MVALPMVLVLLLVLSRGESELDAKIPSTGDATEWRNPHLSMLGSCQPAPSCQKCILSHPSCAWCKQLNFTASGEAEARRCARREELLARGCPLEELEEPRGQQEVLQDQPLSQGARGEGATQLAPQRVRVTLRPGEPQQL |
| 预测分子量 | 42.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITGB7重组蛋白的3篇参考文献示例：
---
1. **文献名称**：*Structural basis of integrin α4β7-MAdCAM-1 recognition in gut homing*
**作者**：Song, G., et al.
**摘要**：该研究解析了重组ITGB7与α4亚基形成的整合素α4β7复合体的晶体结构，揭示了其与黏膜地址素MAdCAM-1的相互作用机制，为炎症性肠病治疗提供结构基础。
2. **文献名称**：*Recombinant β7 integrin regulates T cell migration in inflammatory bowel disease models*
**作者**：Hynes, R.O., et al.
**摘要**：通过表达重组ITGB7蛋白，研究发现其通过调控T细胞向肠道黏膜的迁移，影响小鼠结肠炎模型的疾病进展，提示其作为治疗靶点的潜力。
3. **文献名称**：*Expression and functional characterization of recombinant human integrin β7 in mammalian cells*
**作者**：Smith, M.L., et al.
**摘要**：该文献优化了ITGB7重组蛋白在HEK293细胞中的表达与纯化流程，并验证其与配体结合的功能活性，为后续药物筛选奠定基础。
---
注：上述文献信息为示例性质，实际引用时需核实具体文献来源及准确性。
ITGB7 (Integrin Beta 7) is a critical subunit of heterodimeric integrin receptors that mediate cell-cell and cell-extracellular matrix interactions. It pairs exclusively with either the α4 subunit (forming integrin α4β7) or the αE subunit (forming integrin αEβ7), both playing specialized roles in immune cell trafficking and mucosal immunity. Integrin α4β7 is best known for directing lymphocyte homing to gut-associated lymphoid tissues by binding to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), while αEβ7 facilitates retention of intraepithelial lymphocytes in epithelial layers through E-cadherin interactions.
Recombinant ITGB7 protein is engineered using mammalian or insect expression systems to preserve post-translational modifications and functional epitopes. This biotechnologically produced protein serves as a vital tool for studying integrin-mediated signaling, leukocyte adhesion mechanisms, and inflammatory pathways. Its applications extend to functional assays, antibody development, and drug discovery targeting autoimmune diseases like inflammatory bowel disease (IBD) and multiple sclerosis, where aberrant α4β7 activity contributes to pathology.
Research using ITGB7 recombinant proteins has also illuminated its role in cancer metastasis, particularly in tumor cell colonization of specific tissues. Therapeutic agents blocking α4β7 (e.g., vedolizumab) already demonstrate clinical efficacy, underscoring the protein's biomedical significance. Structural studies utilizing recombinant ITGB7 continue to reveal conformational changes during integrin activation, informing the design of next-generation immunomodulators. As gut immunity and targeted immunotherapy gain prominence, ITGB7 remains a focal point for both basic immunology research and translational therapeutic development.
×
